Live from the NIH registry
Studies recruiting near Fayetteville right now
Top 25 of 126 recruiting studies, sorted by proximity — each links to its official registry page
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Chronic Migraine
Phase 3
Interventional 420 participants sought
Preferred Research Partners - Fayetteville /ID# 270419 — Fayetteville, Arkansas (0.8 mi)
· Sponsor: AbbVie
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer
Phase 3
Interventional 1,000 participants sought
Highlands Oncology Group, PA — Fayetteville, Arkansas (0.8 mi)
· Sponsor: Pfizer
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Non-Small Cell Lung Cancer
Phase 3
Interventional 675 participants sought
Research Site — Springdale, Arkansas (8.2 mi)
· Sponsor: AstraZeneca
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
Metastatic Prostate Cancer
Phase 1, Phase 2
Interventional 283 participants sought
Research Site — Fayetteville, Arkansas (0.8 mi)
· Sponsor: AstraZeneca
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
Attention-Deficit/Hyperactivity Disorder
Phase 4
Interventional 286 participants sought
Preferred Research Partners-NWA, LLC — Fayetteville, Arkansas (0.8 mi)
· Sponsor: Supernus Pharmaceuticals, Inc.
Targeting Components of Distress Tolerance
Distress, Emotional
N/A
Interventional 240 participants sought
University of Arkansas - Fayetteville — Fayetteville, Arkansas (0.8 mi)
· Sponsor: University of Arkansas, Fayetteville
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic
Phase 3
Interventional 680 participants sought
Highlands Oncology Group, PA — Fayetteville, Arkansas (0.8 mi)
· Sponsor: Pfizer
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Oligometastatic Prostate Cancer (OMPC)
Phase 3
Interventional 450 participants sought
Highlands Oncology Group — Fayetteville, Arkansas (0.8 mi)
· Sponsor: Novartis Pharmaceuticals
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
Phase 3
Interventional 600 participants sought
Highlands Oncology Group - Fayetteville — Fayetteville, Arkansas (0.8 mi)
· Sponsor: National Cancer Institute (NCI)
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
Muscle-invasive Urothelial Carcinoma
Phase 2
Interventional 62 participants sought
Highlands Oncology Group. — Springdale, Arkansas (8.2 mi)
· Sponsor: Hoffmann-La Roche
OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages
Eosinophilic Gastrointestinal Disorders (EGIDs), Eosinophilic Esophagitis
N/A
Observational 1,350 participants sought
Arkansas Children's Research Institute — Rogers, Arkansas (18.2 mi)
· Sponsor: Children's Hospital Medical Center, Cincinnati
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8
Phase 3
Interventional 304 participants sought
Highlands Oncology Group - Fayetteville — Fayetteville, Arkansas (0.8 mi)
· Sponsor: National Cancer Institute (NCI)
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Metastatic Non-small Cell Lung Cancer
Phase 3
Interventional 744 participants sought
Research Site — Fayetteville, Arkansas (0.8 mi)
· Sponsor: AstraZeneca
Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma
Phase 2
Interventional 87 participants sought
Highlands Oncology Group - Fayetteville — Fayetteville, Arkansas (0.8 mi)
· Sponsor: National Cancer Institute (NCI)
A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder
Major Depressive Disorder
Phase 2
Interventional 200 participants sought
Woodland Research Northwest LLC — Rogers, Arkansas (18.2 mi)
· Sponsor: Bristol-Myers Squibb
The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder
Attention-Deficit/Hyperactivity Disorder
Phase 2
Interventional 76 participants sought
University of Arkansas — Fayetteville, Arkansas (0.8 mi)
· Sponsor: University of Arkansas, Fayetteville
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Breast Neoplasms, Neoplasm Metastasis
Phase 3
Interventional 800 participants sought
Highlands Oncology Group — Springdale, Arkansas (8.2 mi)
· Sponsor: Eli Lilly and Company
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Intestinal Neoplasms, Gastrointestinal Neoplasms
Phase 3
Interventional 800 participants sought
Highlands Oncology Group — Fayetteville, Arkansas (0.8 mi)
· Sponsor: Pfizer
BostonGene and Exigent Genomic INsight Study
Breast Cancer, Non-small Cell Lung Cancer
N/A
Observational 400 participants sought
Highlands Oncology Group — Rogers, Arkansas (18.2 mi)
· Sponsor: BostonGene
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Major Depressive Disorder
Phase 3
Interventional 450 participants sought
Woodland Research Northwest — Rogers, Arkansas (18.2 mi)
· Sponsor: Xenon Pharmaceuticals Inc.
A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)
Hidradenitis Suppurativa (HS)
Phase 2
Interventional 150 participants sought
Site 119 — Rogers, Arkansas (18.2 mi)
· Sponsor: Spyre Therapeutics, Inc.
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Breast Cancer
Phase 3
Interventional 625 participants sought
Research Site — Springdale, Arkansas (8.2 mi)
· Sponsor: AstraZeneca
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
Bipolar Disorder Type I With Mania or Mania With Mixed Features
Phase 3
Interventional 274 participants sought
Woodland Research Northwest — Rogers, Arkansas (18.2 mi)
· Sponsor: Bristol-Myers Squibb
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Phase 3
Interventional 700 participants sought
Highlands Oncology Group — Springdale, Arkansas (8.2 mi)
· Sponsor: Janssen Research & Development, LLC
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder
Bipolar 1 Disorder
Phase 2
Interventional 250 participants sought
Woodland Research Northwest — Rogers, Arkansas (18.2 mi)
· Sponsor: Rapport Therapeutics Inc.